5
Jun 2026
Favorable lifestyle factors reduce dementia risk across key genetic profiles
With dementia cases expected to nearly triple worldwide by 2050, researchers are increasingly focused on identifying ways to prevent or delay the disease.
Stay Informed!
5
Jun 2026
Modified culture medium speeds up detection of antibiotic resistance
A critical problem with treating Clostridioides difficile infections is the possibility that the pathogen develops resistance to fidaxomicin, an antibiotic often prescribed as a first-line treatment.
5
Jun 2026
American Heart Association introduces new certification for stroke coordinators
Stroke remains a leading cause of death and disability in the United States, underscoring the need for effective, coordinated evidence–based care across hospitals and health systems.
5
Jun 2026
Hidden junk DNA could play decisive role in cancer
Many repetitive regions of the genome have been considered "junk DNA" because the technologies available did not allow them to be studied at sufficient resolution.
5
Jun 2026
Study links pre-bedtime smartphone use to longer teen late nights
A new study to be presented at the SLEEP 2026 annual meeting found that on evenings when adolescents used their smartphone before bedtime more than their own usual, they used their smartphone for longer later that same night, compared with nights when they used their phones less before bedtime.
5
Jun 2026
Major trials show finerenone preserves kidney function beyond diabetes
A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.
5
Jun 2026
Review highlights TIGIT as a promising second-generation immunotherapy target
Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.
5
Jun 2026
Antibody fragment offers safer alternative for Alzheimer disease treatment
In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases).
5
Jun 2026
UK manufacturer supplying Ebola response warns infection-control readiness cannot wait for crisis
As health agencies respond to the current Ebola outbreak in Central Africa, a UK manufacturer supplying water purification products for direct distribution in affected communities is warning that infection-control readiness must be planned long before an emergency takes hold.
5
Jun 2026
Biopsy-driven treatment strategy improves clinical outcomes in psoriatic arthritis
The management of psoriatic arthritis is increasingly focused on the early identification of clinical, immunological, and tissue-based phenotypes predictive of therapeutic response.
